Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines against infectious diseases, with two commercial products: HEPLISAV-B® vaccine and CpG 1018 adjuvant. The company advances CpG 1018 adjuvant through global collaborations for vaccines targeting COVID-19, influenza, plague, shingles, and Tdap.
